<DOC>
	<DOCNO>NCT00538174</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) follow daily oral dos 2.5 , 10 , 20 mg dapagliflozin diabetic Japanese subject administer 14 day</brief_summary>
	<brief_title>Phase I Multiple-Ascending Dose ( Japan )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Japanese male female subject Ages 20 70 year old Established diagnosis T2DM BMI &lt; 32 kg/m2 Fasting glucose â‰¤ 240 mg/dL , antidiabetic diet alone HbA1C 6.0 10.0 % Symptomatic T2DM define polyuria and/or polydipsia within 2 month enrollment History diabetic ketoacidosis hyperosmolar nonketotic syndrome History incontinence bladder dysfunction include nocturia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>